Chas. Pfizer & Co. v. Laboratori Pro-Ter Prodotti Therapeutici S. P. A.

278 F. Supp. 148, 156 U.S.P.Q. (BNA) 493, 1967 U.S. Dist. LEXIS 11387
CourtDistrict Court, S.D. New York
DecidedOctober 6, 1967
Docket67 Civ. 2566
StatusPublished
Cited by12 cases

This text of 278 F. Supp. 148 (Chas. Pfizer & Co. v. Laboratori Pro-Ter Prodotti Therapeutici S. P. A.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Chas. Pfizer & Co. v. Laboratori Pro-Ter Prodotti Therapeutici S. P. A., 278 F. Supp. 148, 156 U.S.P.Q. (BNA) 493, 1967 U.S. Dist. LEXIS 11387 (S.D.N.Y. 1967).

Opinion

MANSFIELD, District Judge.

The defendant Pro-Ter Prodotti Therapeutici, S. p. A. (“Pro-Ter” herein) moves pursuant to Rules 12(b) (2), (3), (4) and (5), F.R.Civ.P., to dismiss the complaint against it, which alleges infringement of plaintiff’s antibiotic (oxytetracycline) patents (U.S. Patents 2,516,080 and 3,017,323) within the district. Pro-Ter, an Italian corporation engaged in manufacture of drugs in Italy, challenges the sufficiency of service of process, the Court’s jurisdiction over its person, and venue, for failure to meet the requirements of 28 U.S.C. § 1400(b), since it neither resides in this district nor has a regular and established place of business here. * The essential facts appear to be as follows:

Pro-Ter has had a representative in the Southern District of New York (the Raritan-Rarisphere corporations, who are named as co-defendants) for four years (Rubenstein Deposition (hereinafter “R.D.”), p. 5). Mr. Ruben-stein, the vice-president of both corporations, has been the officer in charge of Pro-Ter’s business in the United States, having visited Pro-Ter’s plant in Milan and been in charge of extensive relations with Pro-Ter and its customers in the United States. The New York representative offers Pro-Ter’s products for sale subject to the approval of Pro-Ter (R.D. 6), signs applications for Food & Drug Administration certification of Pro-Ter’s products, and receives certain mailings from that agency (R.D. 15-16). One shipment of oxytetracycline has been made into this country by Pro-Ter. It went to Brooklyn (R.D. 22). The representative has transmitted six or seven orders for oxytetracycline which have been accepted by Pro-Ter (but none had been shipped as of the time of the deposition (R.D. 26)), and it has placed advertisements for Pro-Ter in a trade publication (R.D. 34). On some occasions an officer of Pro-Ter has been with the New York representative when the latter talked to prospective purchasers (R.D. 38). Samples of Pro-Ter’s products have been shipped by Pro-Ter to the New York representative (R.D. 49). An officer of the New York representative has represented to a number of drug buyers in the United States that he would sell to them on behalf of Pro-Ter (R.D. 52). When purchases were made the letter of credit ran directly to ProTer (R.D. 64). The New York representative’s only compensation has been a commission based upon actual sales (R. D. 65), and there has been a commission contract in effect between Pro-Ter and Rarisphere (R.D. 72). Pro-Ter does not direct or control the activities of the New York representative, which engages in other business and for other companies (R.D. 67).

*151 There can be no serious doubt about the insufficiency of the foregoing activities to satisfy the requirement of the patent venue statute that the defendant either reside in the district or have a “regular and established place of business” there. 28 U.S.C. § 1400(b); see Ruddies v. Auburn Spark Plug Co., 261 F.Supp. 648 (S.D.N.Y.1966); Brevel Prods. Corp. v. H. & B. American Corp., 202 F.Supp. 824 (S.D.N.Y.1962); Mastantuono v. Jacobsen Mfg. Co., 184 F.Supp. 178 (S.D.N.Y.1960); Bradford Novelty Co. v. Manheim, 156 F.Supp. 489 (S.D.N.Y.1957); Kamkap, Inc. v. Worldsbest Indus., Inc., 140 F.Supp. 854 (S.D.N.Y.1956). See also Railex Corp. v. White Machine Co., 243 F.Supp. 381 (E.D.N.Y.1965). Although recent decisions, Watsco, Inc. v. Henry Valve Co., 232 F.Supp. 38 (S.D.N.Y.1964) and Stiegele v. Jacques Kreisler Mfg. Corp., 213 F.Supp. 494 (S.D.N.Y.1962), indicate a more flexible approach in determining the weight to be given to solicitation activities for purposes of deciding whether they amount to the maintenance of a regular and established business, the conduct here falls short of that found sufficient in those cases. Accordingly, if the plaintiff here were required to satisfy this condition of 28 U.S.C. § 1400(b), Pro-Ter’s motion to dismiss would be granted.

There remains, however, the question of whether venue is governed exclusively by the restrictive patent venue statute, 28 U.S.C. § 1400(b), or whether, at least in the case of a suit against an alien, it may be based on 28 U.S.C. § 1391(d), the general venue statute, which provides that “An alien may be sued in any district”, the term “alien” having been interpreted to include alien corporations. State of Maryland For the Use of Mitchell v. Capital Airlines, Inc., 199 F.Supp. 335 (S.D.N.Y.1961); Japan Gas Lighter Assn. v. Ronson Corp., 257 F.Supp. 219 (D.N.J.1966); Bator v. Boosey & Hawkes, Ltd., 80 F.Supp. 294 (S.D.N.Y.1948) (alien venue rule applied to foreign corporation prior to § 1391 (d)’s enactment). Pro-Ter, relying mainly on the Supreme Court’s decision in Fourco Glass Co. v. Transmirra Prods. Corp., 353 U.S. 222, 77 S.Ct. 787, 1 L.Ed.2d 786 (1957), and the Seventh Circuit’s recent decision in Coulter Electronics Inc. v. A. B. Lars Ljungberg & Co., 376 F.2d 743 (7th Cir. 1967), contends the venue in patent infringement suits must be governed exclusively by 28 U.S.C. § 1400(b), and that it is neither supplemented by, nor dovetails with, § 1391(d).

In Fourco the Supreme Court, in holding that § 1400 (b)’s requirements were exclusive in a suit against a domestic corporation, based its decision on the fact that when Congress re-enacted § 1400(b) in 1948, it expressed no intent (either in the Reviser’s Notes or the text) that it should be supplemented by § 1391(c), after a prior Supreme Court decision clearly held that the requirements of § 1400 (b)’s predecessor (§48 of the Judicial Code, 28 U.S.C. (1940 ed.) § 109) was the sole provision governing venue in a suit against a domestic corporation, and was exclusive with respect to § 1392(a)’s predecessor (§ 52 of the Judicial Code, 28 U.S.C. (1940 ed.) § 113). Stonite Prods. Co. v. Melvin Lloyd Co., 315 U.S. 561, 62 S.Ct. 780, 86 L.Ed. 1026, where the Court held:

“ ‘that Section 48 is the exclusive provision controlling venue in patent infringement proceedings’ and ‘that Congress did not intend the Act of 1897 [which had become § 48 of the Judicial Code, 28 U.S.C. (1940 ed.) § 109] to dovetail with the general provisions relating to the venue of civil suits, but rather that it alone should control venue in patent infringement proceedings.’ ” (Fourco Glass Co. v. Transmirra Prods. Corp., 353 U.S. at 225, 77 S.Ct. at 789, quoting 315 U.S. at 563, 566, 62 S.Ct. at 781, 782.)

As applied to suits against domestic corporations, there were sound reasons supporting the Supreme Court rationale of Congressional intent as to the relationship between § 1400(b) and § 1391 (c).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Day v. Cornér Bank (Overseas) Ltd.
789 F. Supp. 2d 150 (District of Columbia, 2011)
Arnett v. Gerber Scientific, Inc.
575 F. Supp. 770 (S.D. New York, 1983)
Brown v. United States
3 Cl. Ct. 409 (Court of Claims, 1983)
Graham Engineering Corp. v. Kemp Products Ltd.
418 F. Supp. 915 (N.D. Ohio, 1976)
Oliner v. McBride's Industries, Inc.
412 F. Supp. 490 (S.D. New York, 1975)
McDaniel v. Baptist Memorial Hospital
352 F. Supp. 690 (W.D. Tennessee, 1972)
SCM Corporation v. Brother International Corporation
316 F. Supp. 1328 (S.D. New York, 1970)
Bourget v. Government Employees Insurance
48 F.R.D. 29 (D. Connecticut, 1969)
Hawaii v. Standard Oil Co.
301 F. Supp. 980 (D. Hawaii, 1969)

Cite This Page — Counsel Stack

Bluebook (online)
278 F. Supp. 148, 156 U.S.P.Q. (BNA) 493, 1967 U.S. Dist. LEXIS 11387, Counsel Stack Legal Research, https://law.counselstack.com/opinion/chas-pfizer-co-v-laboratori-pro-ter-prodotti-therapeutici-s-p-a-nysd-1967.